Targeted DNA RNA Sequencing Market Size & Growth Forecast 2026–2035, By Segments (Workflow, Application, End Use, Type, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Targeted DNA RNA Sequencing Market size was valued at USD 13.7 Billion in 2025 and is anticipated to grow at a 19.2% CAGR from 2026 to 2035, exceeding USD 79.34 Billion by 2035. The industry revenue for 2026 is assessed at USD 16.04 billion.
Get more details on this report
Request Free Sample ReportTargeted DNA RNA Sequencing Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 45.61% of the market in 2025, supported by advanced genomics infrastructure, routine clinical sequencing, and strong adoption across research, hospitals, and diagnostic laboratories.
- Asia Pacific is forecast to grow at a 21.5% CAGR as investments in genomics capacity, expanding clinical research, and broader sequencing adoption strengthen regional testing capabilities.
Segment Momentum
- Sequencing held a 59.12% share in 2025 because it is the core workflow that generates the molecular data required for routine testing, panel-based research, and sample processing across laboratories.
- Drug Discovery is growing fastest because targeted sequencing helps identify actionable targets, refine candidate selection, and generate focused molecular insights that improve efficiency in development workflows.
Market Expansion Drivers
- Expanding precision medicine adoption driving demand for high-resolution genomic profiling.
- Rising cancer and genetic disease incidence accelerating demand for targeted sequencing solutions.
- Cost-efficient NGS advancements enabling scalable targeted genomic analysis workflows.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Leading players in the targeted DNA RNA sequencing market include Illumina, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (United States), QIAGEN N.V. (Netherlands), Oxford Nanopore Technologies plc (United Kingdom), Agilent Technologies, Inc. (United States), Pacific Biosciences of California, Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As treatment selection becomes increasingly tied to molecular characteristics rather than broad disease categories, healthcare providers and laboratory networks are relying more heavily on targeted panels to identify actionable variants with clinical relevance. This is strengthening demand for the targeted DNA RNA sequencing market because targeted workflows offer the depth, sensitivity, and turnaround needed to support therapy matching, patient stratification, and biomarker-guided decision-making in routine care. In practice, precision medicine programs tend to favor assays that can interrogate defined genomic regions with high confidence, which supports recurring test utilization and reinforces the role of targeted DNA RNA sequencing in clinical diagnostic pathways.
Rising cancer and genetic disease incidence accelerating demand for targeted sequencing solutions
A growing volume of oncology and inherited disease testing is pushing clinicians and diagnostic laboratories toward methods that can detect relevant mutations without the cost and complexity of broader sequencing approaches. This dynamic is contributing to market size growth in the targeted DNA RNA sequencing market, particularly where treatment planning or diagnostic confirmation depends on rapid identification of known pathogenic variants, fusions, or expression markers. As case volumes rise, laboratories increasingly prioritize targeted solutions that fit established clinical workflows, expand testing capacity, and support more consistent reporting for diseases where genomic findings directly shape intervention choices.
Cost-efficient NGS advancements enabling scalable targeted genomic analysis workflows
Improvements in sequencing chemistry, automation, library preparation, and bioinformatics are making targeted assays more practical for high-throughput routine use, lowering operational barriers for hospitals, reference labs, and specialized testing providers. This is encouraging market growth for the targeted DNA RNA sequencing market by improving sample-to-result efficiency and making it easier to run focused panels at a scale aligned with clinical demand. In practice, lower per-sample processing costs and more streamlined data interpretation encourage broader adoption of targeted sequencing over less focused or more resource-intensive methods, especially in settings where reimbursement pressure and workflow standardization strongly influence technology selection.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding precision medicine adoption driving demand for high-resolution genomic profiling | 2.60% | High | North America, Europe | High | Near Term |
| Rising cancer and genetic disease incidence accelerating demand for targeted sequencing solutions | 2.30% | High | North America, Asia Pacific | High | Near Term |
| Cost-efficient NGS advancements enabling scalable targeted genomic analysis workflows | 2.00% | High | North America, Europe | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 45.61% share of the targeted DNA RNA sequencing market in 2025, bolstered by its established genomics research base, broad use of sequencing in clinical and translational workflows, and strong concentration of specialized laboratories and technology providers. The region’s leadership is aided by routine integration of targeted sequencing into oncology research, biomarker discovery, and precision medicine programs, where mature funding channels and advanced laboratory infrastructure help move assays from development into regular use. This operating environment sustains high instrument utilization, repeat consumables demand, and steady adoption across research institutes, hospitals, and diagnostic settings.
Asia Pacific is projected to expand at a 21.5% CAGR over the forecast period in the targeted DNA RNA sequencing market, driven by rising investment in genomics capacity, expanding clinical research activity, and broader adoption of sequencing technologies across rapidly developing healthcare systems. Growth is accelerating as laboratories and medical centers increase use of targeted panels for cancer profiling and inherited disease analysis, while regional institutions continue building local testing capabilities rather than relying solely on external reference networks. The combination of improving access to sequencing platforms and increasing practical use in research and clinical applications is creating a faster adoption curve across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Genomics IntegrationGermany is integrating targeted DNA RNA sequencing into clinical diagnostics and translational research across healthcare institutions. Organizations prioritize validated testing protocols, high-quality genomic analysis, and collaboration between research centers and diagnostic laboratories.
France 🇫🇷
Translational Research SupportFrance advances targeted DNA RNA sequencing through strong biomedical research networks and increasing use in personalized medicine. Healthcare institutions prioritize clinically relevant genomic testing, standardized laboratory practices, and improved patient-specific diagnostic capabilities.
Italy 🇮🇹
Specialized Diagnostic ApplicationsItaly is expanding targeted DNA RNA sequencing across oncology, rare disease diagnostics, and academic research programs. Laboratories are strengthening sequencing infrastructure and bioinformatics expertise to support reliable molecular testing and clinical decision-making.
Japan 🇯🇵
Advanced Molecular DiagnosticsJapan supports targeted DNA RNA sequencing through continued investment in molecular diagnostics, cancer research, and personalized healthcare. Institutions focus on improving sequencing precision, automation, and laboratory efficiency for routine clinical applications.
South Korea 🇰🇷
Genomic Innovation EcosystemSouth Korea continues strengthening its targeted DNA RNA sequencing capabilities through expanding biotechnology research and precision healthcare initiatives. Laboratories emphasize high-throughput sequencing, data analytics, and collaboration between academic and commercial organizations.
United States 🇺🇸
Precision Genomics ExpansionThe U.S. targeted DNA RNA sequencing market benefits from extensive adoption across precision medicine, oncology, and clinical research. Laboratories continue investing in advanced sequencing platforms, bioinformatics capabilities, and standardized workflows to improve diagnostic accuracy and research productivity.
Segment Leadership and Growth Trends
Targeted DNA RNA Sequencing Market Share (%), Workflow, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWithin the targeted DNA RNA sequencing market, Sequencing held the leading position in 2025 with a 59.12% share. Its leadership is underpinned by the fact that sequencing remains the core operational step that generates the primary molecular data required for any targeted DNA and RNA workflow. Demand stays concentrated here because laboratories and research programs must consistently invest in sequencing runs to produce actionable results, making this stage central to routine testing throughput, panel-based research, and sample processing activity across the market.
Data Analysis is emerging as the fastest-growing workflow segment in the targeted DNA RNA sequencing market as users face rising complexity in interpreting targeted panels, variant calls, expression signals, and multi-sample datasets. Growth is being influenced by the practical need to convert sequencing output into reliable biological and clinical insight, which places increasing importance on bioinformatics pipelines, interpretation tools, and workflow efficiency. Compared with sequencing itself, data analysis is gaining stronger momentum because the value of targeted testing increasingly depends on faster, more accurate, and more scalable downstream interpretation.
Application Segment Analysis: Human Biomedical Research (Largest Segment) vs Drug Discovery (Fastest-Growing Segment)
Human Biomedical Research accounted for the largest position in the targeted DNA RNA sequencing market in 2025, holding a 66.54% share. This segment leads because targeted DNA and RNA sequencing is widely used in studying disease mechanisms, biomarker relevance, gene expression, and mutation patterns in human samples, making it a routine tool across translational and academic research settings. Its large share is reinforced through the continued dependence of biomedical investigators on targeted approaches that deliver focused, high-relevance genetic information without the broader cost and complexity of less selective sequencing methods.
Drug Discovery represents the fastest-growing application in the targeted DNA RNA sequencing market, reinforced through the increasing need to identify actionable targets, stratify biological responses, and refine candidate selection earlier in development workflows. The segment is expanding faster than other applications because targeted sequencing offers a practical way to generate focused molecular insight that can guide compound evaluation and mechanism-based research with greater efficiency. As development programs place more emphasis on precision and evidence-driven screening, drug discovery is seeing stronger uptake of targeted sequencing tools.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Workflow | Pre-sequencing, Sequencing, Data Analysis | Sequencing | Data Analysis |
| Application | Human Biomedical Research, Plant & Animal Sciences, Drug Discovery, Others | Human Biomedical Research | Drug Discovery |
| End Use | Academic Research, Hospitals & Clinics, Pharma & Biotech Entities, Others | Hospitals & Clinics | Pharma & Biotech Entities |
| Type | DNA Based Targeted Sequencing, RNA Based Targeted Sequencing | DNA Based Targeted Sequencing | RNA Based Targeted Sequencing |
| Product | Next-Generation Sequencing (NGS), Others | Next-Generation Sequencing (NGS) | Next-Generation Sequencing (NGS) |
Competitive Landscape and Market Positioning
1. Illumina Inc. (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Thermo Fisher Scientific Inc. (United States)
4. QIAGEN N.V. (Netherlands)
5. Oxford Nanopore Technologies plc (United Kingdom)
6. Agilent Technologies Inc. (United States)
7. Pacific Biosciences of California Inc. (United States)
Advancements in genomic analysis are transforming the targeted DNA RNA sequencing market, enabling more precise molecular profiling. Improved sequencing accuracy is enhancing research and clinical diagnostics. Continuous innovation is strengthening genetic analysis capabilities in the targeted DNA RNA sequencing market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Roche | Feb-25 | Roche launched its SBX sequencing technology in Switzerland, providing an ultra-rapid and scalable next-generation sequencing platform. The technology enhances sequencing efficiency for genomic research and clinical applications, strengthening Roche's competitive position in precision medicine and expanding capabilities for targeted DNA and RNA sequencing workflows. |
| Bio-Rad | Jun-24 | Bio-Rad introduced the ddSEQ Single-Cell 3' RNA-Seq Kit to enable rapid and cost-effective single-cell gene expression analysis. The launch expands the company's targeted RNA sequencing portfolio, supporting advanced research in oncology, immunology, and related fields through improved single-cell sequencing capabilities. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Targeted DNA RNA Sequencing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Targeted DNA RNA Sequencing Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the targeted DNA RNA sequencing market?
What are the growth projections for the targeted DNA RNA sequencing industry?
How is precision medicine influencing adoption in the targeted DNA RNA sequencing market?
How are rising disease incidence and cost-efficient NGS advancements shaping demand in the targeted DNA RNA sequencing market?
Why does the Sequencing workflow dominate the targeted DNA RNA sequencing market?
Why is Drug Discovery the fastest-growing application in the targeted DNA RNA sequencing market?
Why does North America dominate the targeted DNA RNA sequencing market?
What is fueling rapid growth of the targeted DNA RNA sequencing market in Asia Pacific?
Who are the leading players in the targeted DNA RNA sequencing landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization